Previous 10 | Next 10 |
home / stock / brtxd / brtxd news
--Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc ...
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to pres...
-- BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to S upply B iologics for C osmetic A pplications in Strategic Agreement --Agreement Represents Initial Venture in to the $62.8 B ...
--Site activation allows for patients in the S tate of New York to participate in the BRTX-100 t rial — --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative ...
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive ...
No D ose L imiting T oxicity (DLT) w as O bserved in the P atients in the S afety R un- I n S egment of S tudy ...
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to pres...
-- Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100-- MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative...
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jeff...
--License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “...
News, Short Squeeze, Breakout and More Instantly...
BioRestorative Therapies Inc Company Name:
BRTXD Stock Symbol:
OTCMKTS Market:
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: ...
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem ® licensing opportunities – – Substantive di...
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX ...